• Pulse Biosciences recently reported first-quarter 2026 results showing a wider net loss of US$18.58 million and basic loss per share of US$0.27, while also missing consensus revenue expectations with about US$0.4 million in sales.
• At the same time, the company released late-breaking, positive first-in-human data for its nPulse Cardiac Catheter System in atrial fibrillation, reinforcing confidence in its non-thermal nsPFA platform with high procedural success, durable rhythm control and a low rate of serious adverse events across 177 treated patients in Europe.
• We’ll now examine how this encouraging atrial fibrillation feasibility data for the nPulse Cardiac Catheter System could reshape Pulse Biosciences’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you need to believe its nanosecond PFA can carve out a real role in atrial fibrillation and thyroid care before cash burn bites too hard. The latest AF data strengthens the near term cardiac catalyst around the nPulse Cardiac Catheter System, but Q1 2026 results again highlight the core risk of rising losses and modest revenue, keeping execution, timelines and funding firmly in focus.

The late breaking Heart Rhythm 2026 feasibility results are especially important because they support Pulse Biosciences’ recent decision to prioritize the nPulse Cardiac Catheter program and launch the NANOPULSE AF pivotal trial in the United States. If the pivotal data and regulatory pathway align with the strong European feasibility signal, this program could become the central driver of the story, with other surgical and soft tissue initiatives playing a more secondary role.

Yet while the trial outcomes look encouraging, the combination of increasing losses, modest revenue and potential future funding needs is something investors should be aware of...

Pulse Biosciences' narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and a $78.6 million earnings increase from -$74.7 million today.

Uncover how Pulse Biosciences' forecasts yield a $22.00 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could grow about 690% a year to US$42.3 million by 2029, which is far more upbeat than the baseline view tied to cautious trial and commercialization risks, and the fresh AF data may either reinforce or challenge those expectations as you compare different possible paths for Pulse Biosciences.

Explore 2 other fair value estimates on Pulse Biosciences - why the stock might be worth as much as 15% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.